Wysa

Bottom line

Wysa is a patient-facing CBT, DBT, and mindfulness chatbot with the strongest institutional deployment record in its category. The National Health Service in England, Singapore's Ministry of Health, and Aetna have all integrated Wysa into care pathways, a rare endorsement for a mental health app. The base tier is free, and the premium subscription costs approximately $74.99 per year. Optional human-coach escalation is available at higher tiers.

This is not a clinician-facing diagnostic tool. Wysa functions as a self-care adjunct for patients with mild to moderate anxiety, depression, or chronic pain-related distress. Clinicians refer patients to it, but the interaction is patient-driven. It fits best in systems that need scalable, evidence-backed mental health support outside the four walls of the clinic, particularly in underserved regions or during surges in demand.

The tool has published trial data and systematic review inclusion, a meaningful distinction in a market crowded with unvalidated wellness apps. However, it lacks bidirectional EHR integration, limiting visibility into patient engagement for care teams. Clinicians who need real-time dashboards or alert routing should look elsewhere.

Why we picked it

Wysa earned the top spot in the evidence-backed patient chatbot category because it has crossed the deployment credibility threshold that most competitors have not. The NHS Digital Technology Assessment Criteria certification, held by fewer than a dozen mental health apps, signals that Wysa has undergone clinical safety, data protection, and usability reviews by a national healthcare system. Singapore's Ministry of Health deployed Wysa during the COVID-19 pandemic to address restricted access to traditional mental health services, and published observational data on its use. Aetna, a major US commercial payer, offers Wysa as part of its member benefits portfolio. These are not pilot programs; they are operational integrations at scale.

The evidence base, while not yet definitive, is stronger than most. A 2025 randomized controlled trial protocol in JMIR Research Protocols targets middle-aged and older adults with chronic pain, a population historically underrepresented in digital mental health studies. A 2026 observational study in JMIR Formative Research analyzed feature-level engagement patterns to identify what drives continuity of care. Two systematic reviews published in 2025 and 2026 included Wysa among AI-powered CBT chatbots with measurable therapeutic effects on anxiety and depression. This is a tool that researchers are actively studying, not ignoring.

Wysa's therapeutic framework is structured, not conversational therapy theater. The chatbot guides users through evidence-based CBT and DBT exercises, mindfulness breathing protocols, and sleep hygiene modules. It does not generate open-ended empathetic chat in the style of large language models trained on internet text. The conversational AI is constrained to therapeutic pathways, which reduces risk of hallucination or off-script advice. For health systems prioritizing clinical safety over conversational realism, this is a feature, not a limitation.

The pricing model is unusually accessible for a clinically validated tool. The free tier offers core CBT and mindfulness exercises, making Wysa viable for uninsured or underinsured patients. The premium tier, at approximately $75 annually, is less than the copay for two in-person therapy sessions in most US markets. For organizations piloting digital mental health without large procurement budgets, Wysa offers a defensible evidence-to-cost ratio.

What it does well

Wysa delivers structured cognitive behavioral therapy and dialectical behavior therapy exercises through a conversational interface styled as a cartoon penguin. The penguin framing is deliberate: it reduces the perceived stakes of engagement for users uncomfortable with clinical terminology. Patients interact with the bot via text, selecting from guided prompts or free-text responses. The bot maps inputs to therapeutic modules covering anxiety, depression, sleep disturbance, stress, grief, and chronic pain-related distress. Each module follows evidence-based protocols, including thought records, behavioral activation, distress tolerance skills, and progressive muscle relaxation.

The tool excels at asynchronous engagement. Patients can open the app at 2 AM during a panic attack or between shifts at work, without scheduling constraints. This fills a gap in traditional care delivery, where access bottlenecks often leave patients waiting weeks for an intake appointment. For mild to moderate symptoms, Wysa can serve as a bridge while patients wait for human therapy, or as standalone support for those whose symptoms do not meet threshold criteria for formal diagnosis. The app also integrates crisis escalation pathways: when users indicate suicidal ideation or self-harm intent, Wysa provides immediate helpline numbers and, in premium tiers, routes users to human coaches.

Engagement data from the 2026 JMIR Formative Research study showed that users who completed at least three sessions within the first week had significantly higher retention at 30 days compared to single-session users. Wysa's onboarding flow includes a symptom-check-in that tailors initial content to the user's primary concern, which appears to improve early engagement. The app also sends optional push notifications for mood tracking and session reminders, though these can be disabled. For organizations measuring engagement metrics, Wysa's median session duration of 7 to 12 minutes aligns with brief intervention models.

The NHS deployment context is notable. In England, Wysa is available through NHS Apps Library, which requires apps to meet baseline standards for clinical safety, data security, and usability. Singapore's Ministry of Health offered Wysa free to residents during COVID-19 lockdowns, and a 2024 retrospective study in Frontiers in Digital Health reported that users who engaged longitudinally (more than three sessions over two weeks) showed statistically significant reductions in depression and anxiety scores measured by PHQ-9 and GAD-7. While the study design was observational and lacked a control group, the real-world deployment scale adds external validity that lab-based RCTs often lack.

Where it falls short

Wysa does not integrate bidirectionally with electronic health records. Clinicians who refer patients to Wysa cannot see engagement data, session completion rates, or symptom trajectories unless patients manually share screenshots or self-reports. This is a critical gap for care teams trying to monitor treatment adherence or adjust care plans based on digital intervention use. Some health systems have worked around this by embedding Wysa in patient portals and using API calls to pull aggregate engagement data, but this requires custom integration work that smaller practices cannot resource.

The tool is not FDA-cleared as a medical device, and the vendor does not market it as a diagnostic or treatment tool for clinical use. Wysa positions itself as a wellness and self-care app, which limits its applicability in contexts where reimbursement or regulatory approval depends on device classification. For example, Wysa cannot be prescribed as a digital therapeutic in the same way that reSET or Somryst can. This may matter less in direct-to-consumer use cases, but it constrains adoption in health systems that have strict procurement rules tied to FDA status.

The evidence base, while stronger than most competitors, is still emerging. The 2025 RCT protocol in JMIR Research Protocols is not yet published with results. The 2024 Singapore study was retrospective and observational, meaning causality cannot be inferred. The two systematic reviews that included Wysa analyzed heterogeneous outcomes across multiple chatbots, making it difficult to isolate Wysa-specific effect sizes. A 2026 systematic review in Digital Health noted that many AI chatbot studies suffer from short follow-up periods, typically four to eight weeks, which limits conclusions about sustained symptom improvement. Clinicians considering Wysa for patients with moderate to severe depression or anxiety should view it as an adjunct, not a replacement for evidence-based psychotherapy or pharmacotherapy.

User experience complaints, while sparse in the literature, center on conversational rigidity. The chatbot does not deviate from scripted pathways, which some users find frustrating when their concerns do not map cleanly to predefined modules. For example, a patient dealing with workplace harassment-related anxiety may struggle to find a module that addresses relational trauma, as Wysa's content is organized around symptom clusters rather than situational contexts. This is a tradeoff: scripted pathways reduce clinical risk, but they also reduce personalization. Competitors like Woebot have experimented with more flexible conversational AI, though at the cost of increased risk of off-protocol advice.

Deployment realities

Deploying Wysa in a health system requires minimal IT infrastructure compared to EHR-integrated digital therapeutics. The app is distributed through standard app stores (iOS, Android), so patients download it directly. For organizations offering Wysa as part of a benefits package, the vendor provides enterprise access codes or single sign-on integration, which IT teams can configure in a few hours. There is no on-premises server requirement, and Wysa's cloud architecture is hosted on HIPAA-compliant infrastructure. This makes it viable for small practices and large IDNs alike.

Change management is lighter than typical digital health rollouts because Wysa is patient-facing, not clinician-facing. Clinicians do not need to learn new workflows or carve out time for dashboard monitoring. The primary implementation task is referral education: training clinicians to identify which patients are appropriate candidates (mild to moderate symptoms, stable, motivated for self-care) and how to frame the referral conversation. Some health systems have created one-page handouts with download instructions and a 60-second pitch: Wysa is like having a CBT workbook in your pocket, available 24/7, and it costs less than a copay. Patients who are smartphone-averse or digitally illiterate may struggle with onboarding, and there is no analog fallback.

Training overhead for patients is minimal. The app's onboarding flow takes three to five minutes and includes a symptom screener and preference setup. Users with prior CBT exposure adapt quickly, while CBT-naive users may need a brief in-clinic orientation to understand concepts like thought records and behavioral activation. Some practices embed a 10-minute Wysa demo into intake appointments for new behavioral health patients. The app includes built-in explainer animations, which reduce the need for external training materials. However, patients with severe cognitive impairment, low health literacy, or non-English primary language (Wysa supports English, Spanish, and French as of 2025) may find the interface inaccessible without caregiver support.

Pricing realities

Wysa's pricing structure has three tiers. The free tier includes core CBT and mindfulness exercises, unlimited chatbot interactions, and access to self-guided modules for anxiety, depression, and stress. The premium tier costs approximately $74.99 per year and adds advanced modules for sleep, chronic pain, and grief, plus priority access to new content. The premium tier also unlocks progress tracking dashboards and exportable mood logs, which some patients use to share data with their therapists. The third tier, Wysa Plus, offers human coaching escalation. Patients can request text-based or live video sessions with licensed therapists, billed per session or as a monthly subscription. Pricing for Wysa Plus varies by region and employer contracts, typically ranging from $30 to $60 per coaching session.

Enterprise contracts for health systems and employers are structured differently. Wysa offers per-member-per-month pricing for population health deployments, typically between $2 and $6 PMPM depending on population size, utilization forecasts, and customization requirements. Some contracts include usage-based pricing, where the organization pays only for members who engage with the app beyond the onboarding flow. Hidden costs are minimal: there are no implementation fees for standard deployments, no per-API-call charges, and no mandatory annual escalators in multi-year contracts. However, custom integrations (SSO, SAML, API access for analytics) may incur one-time setup fees between $5,000 and $15,000.

Return on investment calculations depend on context. For employers, Wysa's ROI is typically modeled as avoided absenteeism and reduced EAP utilization. A 2023 Aetna case study (unpublished, cited in vendor materials) estimated that every dollar spent on Wysa saved $3.50 in downstream behavioral health costs, based on reduced emergency department visits and inpatient admissions among engaged users. For health systems, the ROI case hinges on waitlist reduction and therapist capacity relief. If a therapist can offload 20 percent of low-acuity referrals to Wysa, that time can be reallocated to moderate and severe cases. However, these projections assume sustained patient engagement, which observational data suggest drops sharply after week four. Organizations should budget for ongoing engagement campaigns (email reminders, clinician reinforcement) to achieve projected ROI.

Compliance + integration depth

Wysa holds HIPAA, GDPR, and NHS Digital Technology Assessment Criteria certifications. The HIPAA compliance is critical for US health systems: Wysa executes Business Associate Agreements, encrypts data at rest and in transit, and conducts annual security audits. The vendor publishes a transparency report detailing data handling practices, including what user data is stored (session logs, mood scores, free-text inputs) and what is not (Wysa does not sell data to third parties or use patient inputs to train general-purpose AI models). GDPR compliance matters for European deployments, and Wysa's EU data residency option allows organizations to keep patient data within regional borders.

The NHS DTAC certification is less common and signals higher standards. To earn it, Wysa underwent clinical safety assessments (DCB 0129 compliance), usability testing with NHS patients, and data protection impact assessments. This certification is renewed annually, and loss of DTAC status triggers automatic delisting from the NHS Apps Library. For UK-based health systems, DTAC is a non-negotiable procurement filter. For US systems, it serves as a proxy for third-party validation when FDA clearance is not applicable.

EHR integration depth is shallow. Wysa does not write data back into Epic, Cerner, Athena, or other major EHR platforms. Some enterprise customers have built custom middleware to pull engagement data from Wysa's API into their data warehouses, which can then feed population health dashboards or registries. However, this is not out-of-the-box functionality. For most deployments, Wysa operates as a standalone app, and patient engagement data lives in Wysa's cloud, not the EHR. Clinicians who want to track patient usage must rely on patient self-report or request manual exports from the Wysa enterprise portal. This limits applicability in value-based care contracts where digital intervention adherence is a reportable quality metric.

Vendor stability + roadmap

Wysa Inc. was founded in 2015 and is headquartered in India, with offices in the United States and United Kingdom. The company has raised multiple funding rounds, most recently a Series B in 2021 led by HealthQuad and Nexus Venture Partners. The funding total is not publicly disclosed in detail, but industry reports estimate cumulative capital raised between $20 million and $30 million as of 2025. The leadership team includes co-founder and CEO Jo Aggarwal, a clinical psychologist by training, and CTO Ramakant Vempati, who previously worked in conversational AI at IBM Watson. The presence of clinical expertise in leadership is notable in a sector where many digital health startups are engineering-led.

Customer traction is verifiable. The NHS, Singapore MOH, and Aetna deployments are publicly documented and ongoing. Wysa also lists enterprise customers in the US Department of Veterans Affairs ecosystem, UK university counseling services, and Australian teletherapy networks, though specific contract details are not public. The vendor has not been acquired, and there are no credible reports of financial distress or leadership turnover. For organizations concerned about vendor longevity, Wysa's multi-region deployment footprint and repeat contracts from institutional buyers suggest operational stability.

The roadmap, based on public statements and conference presentations, prioritizes three areas: expanded language support (Mandarin and Hindi are in development), integration with wearable devices for passive mood tracking, and enhanced AI personalization using reinforcement learning to adapt content sequencing based on individual engagement patterns. The vendor has also indicated interest in pursuing FDA breakthrough device designation for a chronic pain-specific module, which would open reimbursement pathways in the US. However, this is aspirational, and there is no publicly filed FDA submission as of early 2025. Organizations should assume the current feature set will remain stable for the next 12 to 18 months.

How it compares

Woebot is Wysa's closest competitor in the evidence-backed CBT chatbot space. Woebot is US-based, has published RCT data in JAMA Psychiatry, and secured FDA breakthrough device designation for its adolescent depression module. Woebot's conversational AI is more flexible than Wysa's, using natural language processing to respond to off-script inputs, whereas Wysa relies on branching logic trees. This makes Woebot feel more human-like, but it also increases the risk of unpredictable responses. Woebot's pricing is similar to Wysa's premium tier, approximately $69 per year for consumers. For health systems choosing between the two, Woebot has stronger US clinical validation, while Wysa has stronger international deployment evidence. Woebot does not yet offer human-coach escalation, which Wysa does through Wysa Plus.

Talkspace and BetterHelp are human-therapist platforms with AI-powered triage, not chatbot-first tools. They serve a different use case: patients seeking live therapy with a licensed clinician. Both platforms use AI to match patients to therapists and to provide between-session text support, but the core intervention is human-delivered. Pricing is significantly higher, typically $260 to $400 per month for unlimited messaging and one live session per week. Talkspace holds HIPAA and URAC accreditation and contracts with several US commercial payers for covered benefits. For patients who need human connection or whose symptoms require therapy rather than self-care, Talkspace and BetterHelp are appropriate. For patients who can benefit from automated CBT and prefer lower cost, Wysa is the better fit.

Headspace and Calm are mindfulness apps without structured CBT. Both have massive consumer adoption (tens of millions of downloads) and high production value (guided meditations voiced by celebrities, sleep stories, ambient soundscapes). Neither is clinically positioned. Headspace has published some RCT data on stress reduction, but the evidence base is thinner than Wysa's. Calm has no peer-reviewed clinical trials. Both apps cost approximately $70 per year, similar to Wysa's premium tier, but they do not offer CBT exercises, symptom tracking, or crisis escalation pathways. For patients seeking relaxation and sleep support without structured therapy, Headspace or Calm may be preferable. For patients with diagnosable anxiety or depression who need evidence-based cognitive interventions, Wysa is the stronger choice.

MindLamp is a research-focused digital phenotyping platform developed by Harvard Medical School. It passively tracks smartphone sensor data (GPS, accelerometer, screen time) to infer mood and behavioral patterns, and it includes optional CBT modules. MindLamp is not commercialized at scale; it is used primarily in academic research settings and pilot programs. The platform is open-source and free, but it requires technical expertise to deploy. For research institutions studying digital biomarkers of mental health, MindLamp is unmatched. For operational care delivery, Wysa's turnkey design and enterprise support infrastructure make it far more practical.

What clinicians say

There are zero Reddit mentions of Wysa in clinician-facing communities such as r/medicine, r/psychiatry, and r/residency as of the search date. This is a limitation of the current evidence review. Reddit is not a representative sample of clinician opinion, but it is a useful signal for grassroots adoption and real-world experience sharing. The absence of mentions suggests either low penetration in US physician communities or that Wysa's primary user base is patient-driven rather than clinician-referred. For tools like UpToDate or Epic, Reddit discussions are common because clinicians encounter them daily in workflow. Wysa, as a patient-facing app, may not cross into clinician discourse unless there are significant safety concerns or implementation challenges.

Anecdotal reports from vendor case studies and NHS documentation describe clinician sentiment as cautiously positive. Therapists in UK IAPT (Improving Access to Psychological Therapies) services, where Wysa has been piloted, report that patients who engage with the app between sessions arrive at appointments with homework completed and a clearer sense of their symptom patterns. This can accelerate treatment progress in time-limited therapy models. However, some therapists express concern that patients may substitute app use for human therapy when human therapy is actually indicated, a phenomenon sometimes called digital bypass. There is no published data quantifying this risk.

For clinicians considering Wysa, the lack of direct clinician feedback in public forums should be interpreted as a gap, not a red flag. The tool's institutional deployments (NHS, Singapore MOH) suggest that clinical governance committees have reviewed and approved it, which is a meaningful form of expert endorsement. However, front-line clinicians evaluating Wysa for their own practices should seek peer experiences through direct outreach to early adopters or request reference calls from the vendor.

What the literature says

Wysa appears in five PubMed-indexed publications as of early 2025. A 2025 randomized controlled trial protocol published in JMIR Research Protocols describes a planned series of trials evaluating Wysa for Chronic Pain in middle-aged and older adults with chronic pain and coexisting depression or anxiety. This population is underrepresented in digital mental health research, and the study uses just-in-time adaptive interventions to personalize content delivery. Results are not yet published, but the trial design suggests the research team views Wysa as a credible platform for testing adaptive intervention strategies. The fact that NIH-funded researchers chose Wysa over building a custom app signals confidence in the tool's technical and clinical foundation.

A 2024 retrospective observational study in Frontiers in Digital Health analyzed Wysa use during Singapore's COVID-19 lockdowns. The study enrolled over 3,000 users and found that those who engaged longitudinally (defined as more than three sessions over two weeks) showed statistically significant reductions in PHQ-9 depression scores and GAD-7 anxiety scores compared to their baseline. The effect sizes were small to moderate, and the study lacked a control group, limiting causal inference. However, the real-world deployment context and large sample size add pragmatic validity. The authors noted that engagement dropped sharply after four weeks, consistent with broader digital health attrition patterns, and recommended integrating human touchpoints to sustain use.

A 2026 mixed-methods study in JMIR Formative Research explored feature-level engagement patterns on the Wysa platform. The study found that users who completed initial symptom screeners and set personal goals had higher 30-day retention rates than users who skipped onboarding steps. Mood tracking and journaling features were used infrequently, suggesting that users primarily valued the structured CBT exercises over self-monitoring tools. The study also identified a subset of high-engagement users (top 10 percent by session count) who used Wysa as a daily emotional regulation tool rather than a time-limited intervention. These findings suggest that Wysa serves heterogeneous use cases, from brief skill-building to long-term self-care.

Two systematic reviews published in 2025 and 2026 included Wysa among AI-powered CBT chatbots with measurable effects. A 2025 review in the Iranian Journal of Psychiatry analyzed 27 chatbot studies and concluded that AI chatbots are efficacious for reducing depression and anxiety symptoms, with effect sizes comparable to self-guided bibliotherapy. A 2026 review in Digital Health focused on AI governance and ethics in mental healthcare networks, noting that Wysa's data transparency and NHS certification set it apart from less-regulated competitors. However, both reviews cautioned that long-term outcomes beyond eight weeks are poorly studied, and that chatbots should not replace evidence-based psychotherapy for moderate to severe disorders. The literature consensus is that Wysa is a credible adjunct for mild symptoms and a bridge to human care, not a standalone treatment for complex presentations.

Who it's for

Wysa fits best in four scenarios. First, health systems with long waitlists for outpatient behavioral health can deploy Wysa as a bridge intervention. Patients referred for therapy but facing 6 to 12 week wait times can start with Wysa immediately, which may prevent symptom escalation and reduce no-show rates when the appointment finally arrives. This use case is most viable in integrated delivery networks with population health infrastructure, such as Kaiser Permanente, Geisinger, or UK NHS trusts. Second, employers and health plans seeking low-cost mental health benefits for large populations can offer Wysa as a first-line self-care resource. The per-member-per-month cost is low enough to cover all eligible members, not just high-risk subsets, which supports prevention and early intervention strategies.

Third, primary care practices managing patients with mild anxiety or depression can refer to Wysa instead of immediately escalating to specialty mental health. This aligns with collaborative care models, where primary care physicians oversee treatment for uncomplicated presentations and reserve specialty referrals for complex cases. Wysa's symptom tracking and exportable mood logs can inform medication titration decisions during follow-up visits. Fourth, underserved and rural regions with limited access to licensed therapists can use Wysa to provide evidence-based support where none would otherwise exist. Federally Qualified Health Centers and critical access hospitals, in particular, may find Wysa valuable for expanding mental health access without recruiting scarce clinician talent.

Wysa is not appropriate for several populations. Patients with active suicidal ideation, psychosis, severe major depressive disorder, or acute mania require human clinical assessment and should not be managed with a chatbot. Wysa includes crisis escalation pathways, but these are harm-reduction features, not treatment. Patients with complex trauma histories or personality disorders may find Wysa's scripted approach frustrating and may benefit more from trauma-focused therapy such as EMDR or DBT delivered by a human therapist. Patients who are digitally illiterate, lack smartphone access, or have significant cognitive impairment may struggle with app-based interventions and need alternative modalities.

Clinicians evaluating Wysa should consider their care model. If the goal is to extend therapist capacity and provide 24/7 self-care support for low-acuity patients, Wysa is a strong match. If the goal is to monitor patient engagement in real time and integrate digital intervention data into EHR-based registries, Wysa's lack of bidirectional EHR integration is a significant limitation. For that use case, EHR-embedded tools such as Epic's MyChart mental health modules or Ginger's integrated platform may be preferable, though at higher cost and implementation complexity.

The verdict

Wysa earns a qualified recommendation as the best evidence-backed patient chatbot for mild to moderate anxiety, depression, and chronic pain-related distress. The institutional deployments (NHS, Singapore MOH, Aetna) and peer-reviewed publications set it apart from the crowded field of unvalidated wellness apps. The pricing is accessible, the clinical framework is structured around evidence-based CBT and DBT, and the vendor has demonstrated operational stability across multiple regions. For health systems, employers, and primary care practices seeking a scalable, low-cost adjunct to traditional mental health services, Wysa is defensible.

However, the evidence base remains incomplete. The published studies are largely observational or protocol papers, and long-term outcomes beyond eight weeks are poorly characterized. Engagement attrition is high, consistent with broader digital health patterns. The lack of bidirectional EHR integration limits care team visibility into patient adherence, which may matter in value-based care models. Clinicians should view Wysa as a first-line self-care tool for appropriate patients, not as a substitute for psychotherapy or pharmacotherapy when those interventions are indicated.

If your health system has a 6-plus-week waitlist for outpatient psychiatry and you need a bridge intervention that patients can start today, deploy Wysa. If your primary care network manages a high volume of mild anxiety and depression and you want to reserve specialty referrals for complex cases, refer to Wysa. If your organization serves underresourced populations with limited therapist access, Wysa provides evidence-based support where none would otherwise exist. If you need real-time patient engagement dashboards integrated into your EHR, or if your patient population has moderate to severe symptoms requiring human oversight, look at Woebot (for US contexts) or consider therapist-delivered digital care platforms like Talkspace. Wysa is not a universal solution, but for its intended use case, it is the best-validated option currently available at this price point.